Titouan Cazaubiel

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Aurore Perrot, Valérie Lauwers‐Cancès, Titouan Cazaubiel et al. · Blood · 2020 · 124 citations

Medicine, Hematology, Oncology +16

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 90 citations

Medicine, Oncology, Pharmacotherapy +17

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot et al. · Blood · 2022 · 62 citations · Full text

Medicine, Hematology, Oncology +8

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau et al. · Clinical Microbiology and Infection · 2024 · 60 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations

Romain Lannes, Mehmet Samur, Aurore Perrot et al. · Journal of Clinical Oncology · 2022 · 45 citations · Full text

Medicine, Genetics, Molecular Genetics +17